Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.
Feld JJ, Forns X, Dylla DE, Kumada H, de Ledinghen V, Wei L, Brown RS Jr, Flisiak R, Lampertico P, Thabut D, Bondin M, Tatsch F, Burroughs M, Marcinak J, Zhang Z, Emmett A, Jacobson IM. Feld JJ, et al. Among authors: de ledinghen v. J Viral Hepat. 2022 Dec;29(12):1050-1061. doi: 10.1111/jvh.13738. Epub 2022 Oct 6. J Viral Hepat. 2022. PMID: 36036117 Free PMC article.
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T; LIDO Study Group; CYTOL study group. Ratziu V, et al. Among authors: de ledinghen v. BMC Gastroenterol. 2006 Feb 14;6:6. doi: 10.1186/1471-230X-6-6. BMC Gastroenterol. 2006. PMID: 16503961 Free PMC article.
Meta-analyses of FibroTest diagnostic value in chronic liver disease.
Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Poynard T, et al. Among authors: de ledinghen v. BMC Gastroenterol. 2007 Oct 15;7:40. doi: 10.1186/1471-230X-7-40. BMC Gastroenterol. 2007. PMID: 17937811 Free PMC article.
Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy.
Martinez SM, Foucher J, Combis JM, Métivier S, Brunetto M, Capron D, Bourlière M, Bronowicki JP, Dao T, Maynard-Muet M, Lucidarme D, Merrouche W, Forns X, de Lédinghen V. Martinez SM, et al. Among authors: de ledinghen v. PLoS One. 2012;7(10):e47715. doi: 10.1371/journal.pone.0047715. Epub 2012 Oct 17. PLoS One. 2012. PMID: 23082200 Free PMC article. Clinical Trial.
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
Poynard T, Vergniol J, Ngo Y, Foucher J, Munteanu M, Merrouche W, Colombo M, Thibault V, Schiff E, Brass CA, Albrecht JK, Rudler M, Deckmyn O, Lebray P, Thabut D, Ratziu V, de Ledinghen V; FibroFrance Study Group; Epic3 Study Group; Bordeaux HCV Study Group. Poynard T, et al. Among authors: de ledinghen v. J Hepatol. 2014 Apr;60(4):706-14. doi: 10.1016/j.jhep.2013.11.016. Epub 2013 Nov 26. J Hepatol. 2014. PMID: 24291240
Prevalence of renal abnormalities in chronic HBV infection: the HARPE study.
Amet S, Bronowicki JP, Thabut D, Zoulim F, Bourliere M, Mathurin P, de Ledinghen V, Benhamou Y, Larrey DG, Janus N, Deray G, Launay-Vacher V, Pol S. Amet S, et al. Among authors: de ledinghen v. Liver Int. 2015 Jan;35(1):148-55. doi: 10.1111/liv.12480. Epub 2014 Mar 3. Liver Int. 2015. PMID: 24502506
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
Poynard T, Vergniol J, Ngo Y, Foucher J, Thibault V, Munteanu M, Merrouche W, Lebray P, Rudler M, Deckmyn O, Perazzo H, Thabut D, Ratziu V, de Ledinghen V; FibroFrance Study Group and the Bordeaux HBV Study Group. Poynard T, et al. Among authors: de ledinghen v. J Hepatol. 2014 Nov;61(5):994-1003. doi: 10.1016/j.jhep.2014.06.027. Epub 2014 Jul 10. J Hepatol. 2014. PMID: 25016224
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S; ASTRAL-1 Investigators. Feld JJ, et al. N Engl J Med. 2015 Dec 31;373(27):2599-607. doi: 10.1056/NEJMoa1512610. Epub 2015 Nov 16. N Engl J Med. 2015. PMID: 26571066 Free article. Clinical Trial.
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study.
Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J, Rasmann N, Messinger D, Tatsch F, Bakalos G, Foster GR; Gen-C study group. Mangia A, et al. Among authors: de ledinghen v. Springerplus. 2016 Nov 18;5(1):1990. doi: 10.1186/s40064-016-3663-6. eCollection 2016. Springerplus. 2016. PMID: 27917361 Free PMC article.
426 results